Nantahala Capital Management LLC Acquires 47,589 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Nantahala Capital Management LLC boosted its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,452,153 shares of the company's stock after buying an additional 47,589 shares during the quarter. Nantahala Capital Management LLC owned approximately 2.12% of Amylyx Pharmaceuticals worth $5,489,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. grew its position in shares of Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after acquiring an additional 4,883 shares during the period. Fox Run Management L.L.C. purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $45,000. Alpine Global Management LLC purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $45,000. RPO LLC bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at $46,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $53,000. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX traded up $0.18 during midday trading on Friday, hitting $5.32. 759,329 shares of the company traded hands, compared to its average volume of 1,232,948. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $7.27. The firm has a market cap of $473.93 million, a P/E ratio of -1.39 and a beta of -0.53. The stock has a 50-day moving average of $3.88 and a 200-day moving average of $4.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million for the quarter. Sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bernhardt G. Zeiher bought 10,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at $37,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at $11,108,327.09. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,509 shares of company stock worth $222,586. Corporate insiders own 11.70% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AMLX shares. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Mizuho upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price target for the company from $3.00 to $7.00 in a research note on Monday, April 7th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Amylyx Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.